Portfolio News

eSight and CNIB Announce National Partnership to Benefit Canadians with Sight Loss

In honour of World Sight Day, eSight, a Canadian-based world leader in vision technology, is proud to announce a new partnership with CNIB, a non-profit organization driven to change what it means to be blind today. The partnership, the first of its kind for eSight, will expand access of its flagship product, eSight 3, to individuals living with sight loss in Canada. Read more >>
Read more...

eSight 3 Approved on the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule

eSight, a world leader in vision technology, announced the approval of eSight 3 – advanced sight-enhancing glasses for those living with visual impairments -- on the United States Department of Veterans Affairs (VA) Federal Supply Schedule (FSS). The registration allows eSight to be included on the FSS through December 2023. Read more >>
Read more...

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia. Read more >>
Read more...

MarTech Interview with Lynn Browne and Mollie Kehoe, Co-Founders at BrandVerge

How did you get into technology? What inspired you to start BrandVerge? Lynn: I think what really inspired us to do both, is personal frustration in our professional careers. Mollie: When we sat down and really thought about it, there’s so many technologies that have disrupted and helped make our personal lives easier. Read more >>
Read more...

New technology may aid emergency preparedness

The Department of Health and Human Services (HHS) has earmarked funds to aid the development of new technology that could bolster emergency preparedness by producing platelets outside the human body. If the two-year, $4.9 million agreement between HHS Biomedical Advanced Research and Development Authority (BARDA) and Platelet BioGenesis, Inc. (PBG) of Cambridge, Mass., produces the desired results, the technology would improve emergency preparedness by making additional blood products available to save lives during a radiological or nuclear emergency. Read more...
Read more...